@article{ATM16844,
author = {Hidekatsu Yanai},
title = {Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes},
journal = {Annals of Translational Medicine},
volume = {5},
number = {23},
year = {2017},
keywords = {},
abstract = {The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial demonstrated that one of sodium-glucose cotransporter 2 inhibitors (SGLT2i), empagliflozin, reduced all-cause death, death from cardiovascular causes and hospitalization for heart failure when given in addition to standard care in patients with type 2 diabetes at high cardiovascular risk (1), giving us a big surprise and a question to solve whether this result is a drug effect or a class effect.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/16844}
}